🇺🇸 FDA
Patent

US 10591471

Suppression of SPLA2-integrin binding for treating an inflammatory condition or suppressing cell proliferation

granted A61KA61K38/00A61K38/177

Quick answer

US patent 10591471 (Suppression of SPLA2-integrin binding for treating an inflammatory condition or suppressing cell proliferation) held by The Regents of the University of California expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K38/00, A61K38/177, A61P, A61P29/00